Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk

Current Opinion in HIV and AIDS

Volumn 9, Issue 1, 2014, Pages 34-40

  Borges, Álvaro H ^a   Dubrow, Robert ^b   Silverberg, Michael J ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DIVISION OF RESEARCH   (United States)

Author keywords

antiretroviral therapy; cancer; HIV; inflammation

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ANTIVIRAL THERAPY; BLOOD CLOTTING; CANCER INCIDENCE; CANCER RISK; CARCINOGENICITY; CD4 LYMPHOCYTE COUNT; CHRONIC INFLAMMATION; COMBINATION ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALIGNANT NEOPLASTIC DISEASE; NON AIDS DEFINING MALIGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SECONDARY ANALYSIS; TIME TO TREATMENT; VIRUS LOAD; VIRUS REPLICATION;

ANTI-RETROVIRAL AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; NEOPLASMS; RISK FACTORS;

EID: 84892366376     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000025     Document Type: Review

References (91)

1. Centers for Disease Control (CDC). Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men-New York City and California. MMWR Morb Mortal Wkly Rep 1981; 30: 305-308
2. Hymes KB, Cheung T, Greene JB, et al. Kaposi's sarcoma in homosexual men: A report of eight cases. Lancet 1981; 2: 598-600
3. Centers for Disease Control (CDC). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1-19
4. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011; 103: 753-762
5. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS 2009; 23: 2337-2345
6. Dubrow R, Silverberg MJ, Park LS, et al. HIV infection, aging, and immune function: Implications for cancer risk and prevention. Curr Opin Oncol 2012; 24: 506-516
7. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-Analysis. Lancet 2007; 370: 59-67
8. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148: 728-736
9. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 2551-2559
10. Shiels MS, Cole SR, Kirk GD, Poole C. A meta-Analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009; 52: 611-622
11. Silverberg MJ, Leyden W, Warton EM, et al. HIV infection status, immunodeficiency, and the incidence of nonmelanoma skin cancer. J Natl Cancer Inst 2013; 105: 350-360
12. Franzetti M, Adorni F, Parravicini C, et al. Trends and predictors of non AIDSdefining cancers in men and women with HIV infection. A single-institution retrospective study before and after the introduction of HAART. J Acquir Immune Defic Syndr 2013; 62: 414-420
13. Calabresi A, Ferraresi A, Festa A, et al. Incidence of AIDS-defining cancers and virus-related and nonvirus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of northern Italy, 1999-2009. HIV Med 2013; 14: 481-490
14. Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27: 973-979
15. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-Associated cancers among persons with AIDS. J Natl Cancer Inst 2009; 101: 1120-1130
16. Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012; 54: 1026-1034
17. Piketty C, Selinger-Leneman H, Bouvier AM, et al. Incidence of HIV-related anal cancer remains increased despite long-Term combined antiretroviral treatment: Results from the French hospital database on HIV. J Clin Oncol 2012; 30: 4360-4366
18. D'Souza G, Wiley DJ, Li X, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008; 48: 491-499
19. Thompson LD, Fisher SI, Chu WS, et al. HIV-Associated Hodgkin lymphoma: A clinicopathologic and immunophenotypic study of 45 cases. Am J Clin Pathol 2004; 121: 727-738
20. Goedert JJ, Bower M. Impact of highly effective antiretroviral therapy on the risk for Hodgkin lymphoma among people with human immunodeficiency virus infection. Curr Opin Oncol 2012; 24: 531-536
21. Albini L, Calabresi A, Gotti D, et al. Burden of Non-AIDS-defining and nonvirus-related cancers among HIV-infected patients in the combined antiretroviral therapy era. AIDS Res Hum Retroviruses 2013; 29: 1097-1104
22. Borges AH, Silverberg MJ, Wentworth D, et al. Predicting risk of cancer during HIV infection: The role of inflammatory and coagulation biomarkers. AIDS 2013; 27: 1433-1441
23. Lifson AR, Neuhaus J, Arribas JR, et al. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health 2010; 100: 1896-1903
24. Lifson AR, Lando HA. Smoking and HIV: Prevalence, health risks, and cessation strategies. Curr HIV/AIDS Rep 2012; 9: 223-230
25. Grulich AE, Jin F, Poynten IM, Vajdic CM. HIV, cancer, and aging. Sex Health 2011; 8: 521-525
26. Engels EA. Non-AIDS-defining malignancies in HIV-infected persons: Etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS 2009; 23: 875-885
27. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62: 141-155
28. Guiguet M, Boué F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDHANRS CO4): A prospective cohort study. Lancet Oncol 2009; 10: 1152-1159
29. Reekie J, Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and nonacquired immunodeficiency syndrome-defining malignancies. Cancer 2010; 116: 5306-5315
30. Bräu N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A US Canadian multicenter study. J Hepatol 2007; 47: 527-537
31. Achenbach CJ, Cole SR, Kitahata MM, et al. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS 2011; 25: 691-700
32. Riedel DJ, Mwangi EI, Fantry LE, et al. High cancer-related mortality in an urban, predominantly African-American, HIV-infected population. AIDS 2013; 27: 1109-1117
33. Monforte AD, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22: 2143-2153
34. Bedimo RJ, McGinnis KA, Dunlap M, et al. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: Impact of immunosuppression. J Acquir Immune Defic Syndr 2009; 52: 203-208
35. Kesselring A, Gras L, Smit C, et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2011; 52: 1458-1465
36. Helleberg M, Kronborg G, Larsen CS, et al. CD4 decline is associated with increased risk of cardiovascular disease, cancer, and death in virally suppressed patients with HIV. Clin Infect Dis 2013; 57: 314-321
37. Bruyand M, Thié baut R, Lawson-Ayayi S, et al. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis 2009; 49: 1109-1116
38. Zhou F, Xue M, Qin D, et al. HIV-1 Tat promotes Kaposi's sarcoma-Associated herpesvirus (KSHV) vIL-6-induced angiogenesis and tumorigenesis by regulating PI3K/PTEN/AKT/GSK-3b signaling pathway. PLoS One 2013; 8: E53145
39. Amini S, Khalili K, Sawaya BE. Effect of HIV-1 Vpr on cell cycle regulators. DNA Cell Biol 2004; 23: 249-260
40. Harrod R, Nacsa J, Van Lint C, et al. Human immunodeficiency virus type-1 Tat/co-Activator acetyltransferase interactions inhibit p53Lys-320 acetylation and p53-responsive transcription. J Biol Chem 2003; 278: 12310-12318
41. Wang X, Singh S, Jung HY, et al. HIV-1 Vpr protein inhibits telomerase activity via the EDD-DDB1-VPRBP E3 ligase complex. J Biol Chem 2013; 288: 15474-15480
42. Nunnari G, Smith JA, Daniel R. HIV-1 Tat and AIDS-Associated cancer: Targeting the cellular anticancer barrier? J Exp Clin Cancer Res 2008; 27: 3
43. Corallini A, Campioni D, Rossi C, et al. Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. AIDS 1996; 10: 701-710
44. Vogel J, Cepeda M, Enk A, et al. The HIV tat gene is a promoter of epidermal skin tumors. Int J Oncol 1995; 7: 727-733
45. Altavilla G, Caputo A, Lanfredi M, et al. Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene. Am J Pathol 2000; 157: 1081-1089
46. El-Sadr WM, Lundgren J, Neaton JD, et al. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296
47. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: E203
48. Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007; 21: 1957-1963
49. Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104: 1505-1511
50. Hessol NA, Pipkin S, Schwarcz S, et al. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 2007; 165: 1143-1153
51. Crum-Cianflone NF, Hullsiek KH, Marconi V, et al. The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2009; 51: 305-309
52. Krishnan S, Schouten JT, Jacobson DL, et al. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naive subjects after antiretroviral treatment initiation: An ACTG longitudinal linked randomized trials analysis. Oncology 2011; 80: 42-49.
53. Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3'-Azido-2',3'-dideoxythymidine (AZT): Tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997; 89: 1602-1608
54. National Toxicology Program. Toxicology and carcinogenesis studies of mixtures of 3'-Azido-3'-deoxythymidine (AZT), lamivudine (3TC), nevirapine (NVP), and nelfinavir mesylate (NFV) (Cas Nos. 30516-87-1, 134678-17-4, 129618-40-2, 159989-65-8) in B6C3F1 Mice (transplacental exposure studies). Natl Toxicol Program Tech Rep Ser 2013; 569: 1-212
55. Chao C, Leyden WA, Xu L, et al. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS 2012; 26: 2223-2231
56. Bruyand M, Ryom L, Shepherd L, et al. Cancer risk and use of PI or NNRTIbased combination antiretroviral therapy (cART): The D: A: D study. In: Program and abstracts of the XX Conference on Retroviruses and Opportunistic Infections: 2-6 March 2013; Atlanta, USA. Abstract Q-1002
57. Mbang P, Kowalkowski M, Chiao E. The effect of protease inhibitors on the incidence of HIV-Associated squamous cell carcinoma of the anus. In: Program and abstracts of the XX Conference on Retroviruses and Opportunistic Infections: 2-6 March 2013; Atlanta, USA. Abstract Q-1002
58. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27: 884-890
59. Varadarajan J, McWilliams MJ, Hughes SH. Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations. Proc Natl Acad Sci U S A 2013; 110: 14747-14752
60. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007; 196: 304-312
61. Sabin CA, Cooper DA, Collins S, Schechter M. Rating evidence in treatment guidelines: A case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons. AIDS 2013; 27: 1839-1846
62. de Cock KM, El-Sadr WM. When to start ART in Africa: An urgent research priority. N Engl J Med 2013; 11: 886-889
63. Lundgren JD, Babiker AG, Gordin FM, et al. When to start antiretroviral therapy: The need for an evidence base during early HIV infection. BMC Med 2013; 11: 148
64. Franco RA, Saag MS. When to start antiretroviral therapy: As soon as possible. BMC Med 2013; 11: 147
65. Department of Health and Human Services: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington DC; 2013. [http: // aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
66. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012; 13: 1-85
67. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Geneva; 2013. [http: //whqlibdoc.who.int/ publications/ 2010/9789241599764-eng.pdf
68. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505
69. Biggar RJ, Chaturvedi AK, Goedert JJ, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99: 962-972
70. Polesel J, Clifford GM, Rickenbach M, et al. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 2008; 22: 301-306
71. Clifford GM, Franceschi S. Cancer risk in HIV-infected persons: Influence of CD4 count. Future Oncol 2009; 5: 669-678
72. Bower M, Weir J, Francis N, et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. AIDS 2009; 23: 1701-1706
73. van der Snoek EM, van der Ende ME, den Hollander JC, et al.Use of highly active antiretroviral therapy is associated with lower prevalence of anal intraepithelial neoplastic lesions and lower prevalence of human papillomavirus in HIVinfected men who have sex with men. Sex Transm Dis 2012; 39: 495-500
74. Firnhaber C, Westreich D, Schulze D, et al. Highly active antiretroviral therapy and cervical dysplasia in HIV-positive women in South Africa. J Int AIDS Soc 2012; 15: 17382
75. Blitz S, Baxter J, Raboud J, et al. Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. J Infect Dis 2013; 208: 454-462
76. Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent antiangiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 8: 225-232
77. Toschi E, Sgadari C, Malavasi L, et al. Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasomeindependent block of angiogenesis and matrix metalloproteinases. Int J Cancer 2011; 128: 82-93
78. Hecht M, Harrer T, Büttner M, et al. Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system. AIDS 2013; 27: 2031-2040
79. Sciamanna I, Landriscina M, Pittoggi C, et al. Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene 2005; 24: 3923-3931
80. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197: 1133-1144
81. Grinsztejn B, Hosseinipour M, Swindells S, et al. Effect of early versus delayed initiation of antiretroviral therapy (ART) on clinical outcomes in the HPTN 052 randomized clinical trial. In: Program and abstracts of the XIX International AIDS Conference: 22-27 July 2012. Washington DC; [Abstract THLBB05
82. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363: 257-265
83. European AIDS Clinical Society: European Guidelines for treatment of HIV infected adults in Europe. Paris; 2012. [http: //www. europeanaidsclinicalsociety. org/images/stories/EACS-Pdf/EacsGuidelines-v6.1- 2edition.pdf
84. Babiker AG, Emery S, Fä tkenheuer G, et al. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2013; 10: S5-S36
85. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201: 1788-1795
86. Rönsholt FF, Ullum H, Katzenstein TL, et al. Persistent inflammation and endothelial activation in HIV-1 infected patients after 12 years of antiretroviral therapy. PLoS One 2013; 8: E65182
87. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4 T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187: 1534-1543
88. Overton ET, Kitch D, Benson CA, et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis 2013; 56: 1471-1479
89. Chao C, Xu L, Abrams DI, et al. HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons. AIDS 2011; 25: 1771-1777
90. Breen EC, van der Meijden M, Cumberland W, et al. The development of AIDS-Associated Burkitt's/small noncleaved cell lymphoma is preceded by elevated serum levels of interleukin 6. Clin Immunol 1999; 92: 293-2999
91. Breen EC, Hussain SK, Magpantay L, et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-Associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev 2011; 20: 1303-1314